Equity Capital Markets

Allogene Therapeutics, Inc.

04/26
d
Piper Sandler served as bookrunner for Allogene Therapeutics, Inc. on its follow-on offering
Sub-Type
Follow-On Offering
Sector
Healthcare
Sub-Sector
Biopharma

Related Transactions

All Transactions
e
Nektar Therapeutics
Follow-On Offering
Active Bookrunner
$65.2 Million
s
Southern First Bancshares
Follow-On Offering
Sole Bookrunner
d
Allogene Therapeutics, Inc.
Follow-On Offering
Passive Bookrunner
$450.0 Million
e
Atlas Energy Solutions
Convertible Senior Notes
Passive Bookrunner
e
Tamboran Resources
Confidentially Marketed Follow-On Offering
Co-Manager
w
Inovio Pharmaceuticals, Inc.
Confidentially Marketed Follow-On Offering
Financial Advisor
s
HMH Holding Inc.
Initial Public Offering
Joint Bookrunner
w
Flowco
Confidentially Marketed Follow-On Offering
Lead Bookrunner
e
CytomX Therapeutics Inc.
Follow-On Offering
Active Bookrunner
$538.0 Million
s
MiniMed Inc.
Initial Public Offering
Passive Bookrunner
$413.7 Million
d
Nurix
ATM Program Common Stock
Sole Placement Agent
3
Medline Industries
Follow-On
Passive Bookrunner
$50.0 Million
e
Bridgewater Bancshares
ATM Program Common Stock
Sole Placement Agent
s
Zura Bio
Confidentially Marketed Follow-On Offering
Active Bookrunner
$400.0 Million
s
Generate Biomedicines, Inc.
Initial Public Offering
Passive Bookrunner
$170.0 Million
g
Innovex Downhole Solutions, Inc
Follow-On Offering
Active Bookrunner

© 2026 Piper Sandler Companies. Since 1895. All rights reserved.